Induction of amelogenin and ameloblastin by insulin and insulin-like growth factors (IGF-I and IGF-II) during embryonic mouse tooth development in vitro.
Insulin and insulin-like growth factors (IGF-I and IGF-II) are considered pleiotropic, acting as both mitogen and differentiation factors. Several investigators have demonstrated the expression of insulin, IGFs, their cognate receptors and IGF binding proteins during tooth morphogenesis. Previous work done in our laboratory indicated that exogenous insulin and IGFs induce the accumulation of enamel extracellular matrix on mouse mandibular molars cultured in a serumless, chemically defined medium. In order to determine the level of control of these factors in the induction of enamel biomineralization, we designed experiments to quantitate mRNAs for enamel specific-gene products. Mandibular first molars (MI) obtained from E15 Swiss Webster mice were placed in organ culture in the presence of insulin (1,000 ng/ml), IGF-I (100 ng/ml) or IGF-II (100 ng/ml) for 6, 12 and 18-days. At termination date, the RNA was extracted and the concentration of mRNAs for amelogenin, tuftelin and ameloblastin were determined using a quantitative competitive reverse transcription-polymerase chain reaction (RT-PCR) technique (PCR mimic). Our results showed that after 6-days in culture; treatment with insulin, IGF-I and IGF-II increased the synthesis of amelogenin and ameloblastin. In contrast, the expression of tuftelin mRNA was not affected by either factor. In conclusion, our studies showed that the increase in enamel matrix formation by overexpression of IGFs is the result of transcriptional regulation of enamel specific proteins like amelogenin and ameloblastin but not tuftelin. These studies also suggest that the regulatory mechanisms controlling tuftelin gene expression are different than the mechanisms regulating ameloblastin and amelogenin transcription.
Takahashi
K
K
Craniofacial Development Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Yamane
A
A
Bringas
P
P
Caton
J
J
Slavkin
H C
HC
Zeichner-David
M
M
D053523:Amelogenin; D000818:Animals; D003746:Dental Enamel Proteins / Q000096:biosynthesis* / Q000235:genetics; D007328:Insulin / Q000494:pharmacology*; D007334:Insulin-Like Growth Factor I / Q000494:pharmacology*; D007335:Insulin-Like Growth Factor II / Q000494:pharmacology*; D051379:Mice; D008963:Molar / Q000187:drug effects / Q000196:embryology / Q000378:metabolism*; D009924:Organ Culture Techniques; D016133:Polymerase Chain Reaction / Q000379:methods; D014158:Transcription, Genetic / Q000187:drug effects
C490889:AMBN protein, human; C490890:Ambn protein, mouse; D053523:Amelogenin; C507200:Amelx protein, mouse; D003746:Dental Enamel Proteins; D007328:Insulin; C038456:tuftelin; D007334:Insulin-Like Growth Factor I; D007335:Insulin-Like Growth Factor II